Public Employees Retirement System of Ohio Buys New Position in Ralliant Corporation $RAL

Key Points

• Ohio’s public employees’ pension system purchased 33,603 Ralliant shares worth approximately $2.47 million during the second quarter, joining several major institutions that initiated or increased positions.
• Analysts maintain a generally positive outlook, with Ralliant receiving a “Moderate Buy” consensus rating and an average price target of $75.70, compared with its reported opening price of $63.46.
• Ralliant beat quarterly earnings expectations, reporting $0.68 in EPS versus the $0.63 consensus estimate, while issuing fiscal 2026 EPS guidance of $2.76–$2.90 and declaring a quarterly dividend of $0.05 per share.

Public Employees Retirement System of Ohio purchased a new position in shares of Ralliant Corporation (NYSE:RAL - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,603 shares of the company's stock, valued at approximately $2,474,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. purchased a new position in Ralliant during the 2nd quarter worth $1,039,481,000. Viking Global Investors LP purchased a new stake in shares of Ralliant in the second quarter valued at about $257,200,000. State Street Corp bought a new position in shares of Ralliant during the second quarter valued at about $213,096,000. Millennium Management LLC boosted its holdings in Ralliant by 172.4% during the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company's stock worth $253,175,000 after purchasing an additional 3,147,660 shares during the last quarter. Finally, Flossbach Von Storch SE purchased a new position in Ralliant during the second quarter worth about $222,460,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Royal Bank Of Canada increased their price objective on shares of Ralliant from $71.00 to $73.00 and gave the company a "sector perform" rating in a research note on Friday, July 31st. Truist Financial reaffirmed a "buy" rating and issued a $82.00 target price (up from $68.00) on shares of Ralliant in a report on Friday, July 31st. Vertical Research downgraded Ralliant from a "buy" rating to a "hold" rating and set a $65.00 price target for the company. in a research report on Wednesday, May 27th. Wall Street Zen lowered Ralliant from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 30th. Finally, Barclays boosted their price objective on Ralliant from $52.00 to $67.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Ralliant has an average rating of "Moderate Buy" and an average target price of $75.70.

Ralliant Stock Up 1.1%

Ralliant stock opened at $63.46 on Friday. The firm has a 50 day moving average price of $67.52 and a 200-day moving average price of $57.10. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The company has a market capitalization of $7.02 billion, a P/E ratio of -5.85, a P/E/G ratio of 2.36 and a beta of 1.54.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The business had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, equities analysts predict that Ralliant Corporation will post 2.87 EPS for the current year.

Ralliant Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant's dividend payout ratio is currently -1.84%.

Insider Buying and Selling at Ralliant

In related news, CEO Tamara S. Newcombe sold 12,936 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the sale, the chief executive officer directly owned 251,967 shares in the company, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $72.00, for a total transaction of $436,464.00. Following the sale, the senior vice president directly owned 31,668 shares in the company, valued at approximately $2,280,096. This trade represents a 16.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by corporate insiders.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.